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Abstract
Background:  Chronic obstructive pulmonary disease (COPD) is a health problem that is
becoming increasingly attended-to in Primary Care (PC). However, there is a scarcity of health-
care programs and studies exploring the implementation of Clinical Practice Guidelines (CPG). The
principal objective of the present study is to evaluate the effectiveness of a combined strategy
directed towards health-care professionals and patients to improve the grade of clinical control and
the quality-of-life (QoL) of the patients via a feedback on their state-of-health. A training plan for
the health-care professionals is based on CPG and health education.
Method/Design: Multi-centred, before-after, quasi experimental, prospective study involving an
intervention group and a control group of individuals followed-up for 12 months. The patients
receive attention from urban and semi-urban Primary Care Centres (PCC) within the
administrative area of the Costa de Ponent (near Barcelona). All the pacients corresponding to the
PCC of one sub-area were assigned to the intervention group and patients from the rest of sub-
areas to the group control. The intervention includes providing data to the health-care
professionals (clinician/nurse) derived from a clinical history and an interview. A course of training
focused on aspects of CPG, motivational interview and health education (tobacco, inhalers, diet,
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physical exercise, physiotherapy). The sample random includes a total of 801 patients (≥ 40 years
of age), recorded as having COPD, receiving attention in the PCC or at home, who have had at
least one clinical visit, and who provided written informed consent to participation in the study.
Data collected include socio-demographic characteristics, drug treatment, exacerbations and
hospital admissions, evaluation of inhaler use, tobacco consumption and life-style and health-care
resources consumed. The main endpoints are dyspnoea, according to the modified scale of the
Medical Research Council (MRC) and the QoL, evaluated with the St George's Respiratory
Questionnaire (SGRQ). The variables are obtained at the start and the end of the intervention.
Information from follow-up visits focuses on the changes in life-style activities of the patient.
Discussion: This study is conducted with the objective of generating evidence that shows that
implementation of awareness programs directed towards health-care professionals as well as
patients in the context of PC can produce an increase in the QoL and a decrease in the disease
exacerbation, compared to standard clinical practice.
Trial Registration: Clinical Trials.gov Identifier: NCT00922545;
Background
Chronic obstructive pulmonary disease (COPD) is
described as a disease of restricted air flow, not totally
reversible and, in general, progressive. It is associated with
an abnormal inflammatory response of the lung to toxic
particles and gases, especially tobacco, with important
systemic repercussions [1]
It is a very prevalent health problem worldwide and is a
frequent cause of morbidity and mortality in developed
countries. Studies conducted in Spain show a prevalence
of between 8 and 12% in the population ≥ 40 years of age
and 20% in those ≥ 65 years of age [2-5]. In our environ-
ment it represents a quarter of all-cause death, with an
overall rate of 33 cases/100,000 individuals/year [6].
Based on several studies, the calculated worldwide level in
the year 2020 will be the 5th highest cause of invalidity
and the 3rd highest cause of death [7].
COPD is responsible for between 10-12% of the consulta-
tions in Primary Care (PC) and 35-40% of the consulta-
tions in specialist care. It is responsible for 7% of hospital
admissions and 35% of chronic incapacity with respect to
productive labour [6] and, as such, the social, health-care
and economic impact is high. The cost of this disease
accounts for 2% of the annual budget of the Ministry of
Health and Consumer Affairs [6]. It is calculated that the
patient with COPD generates a mean direct cost of 1,876
€/year; the greater part of the cost corresponding to the
hospitalisation (43.8%) followed by drug costs (40.8%)
for the control of the disease [8].
The approach to COPD, according to the different clinical
guidelines [6,9] includes prevention, diagnosis, follow-up
with pharmaceutical as well as non-pharmaceutical treat-
ment, and the coordination between the PC and the
health-care provision facilities (specialist care and hospi-
talisation).
The tobacco habit is the best known causal factor of the
disease [9]. Smoking has a high prevalence of 29.5% in
the general population [10] and of 80% in patients with
COPD [11,12]. Cessation of smoking is the only measure
that can prevent the disease and modify its clinical course
[9,13]. Several studies indicate that, at the level of PC,
there is low implementation of structured programs for
the cessation of smoking [14,15]. Several questionnaires
have shown that an important proportion of the patients
with COPD do not identify smoking as the principal cause
of their disease, and a high proportion had never
attempted to quit smoking [16,17].
Several international studies [9,18-21] have shown that a
high proportion of patients with COPD are non-diag-
nosed, including those in the advanced stages of the dis-
ease. In our environment, only 22% of the patients had
been diagnosed previously [22,23]. The reasons for delay
and of under-diagnosis are due, in part, to the lack of
awareness by the patients and, as well, by their own family
doctor. The term COPD appears not to be recognised nor
understood by the general population. According to a
study conducted in Spain, only 9% of the general popula-
tion have some knowledge of COPD and, among those
individuals with chronic symptoms and high risk of
COPD, 33.2% had never consulted their general practi-
tioner [24]. With respect to clinicians, there needs to be an
increase in the awareness of COPD, especially at the PC
level where, for example, there is a low level of spirometric
testing [24]; a technique that is vital for the diagnosis of
the disease. Recent studies indicate that only between 38
and 45% of the patients at high risk of COPD have had a
spirometric test performed by the family doctor in the
PCC [20,24-26].BMC Public Health 2009, 9:442 http://www.biomedcentral.com/1471-2458/9/442
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In patient follow-up, it is important to highlight that clin-
ical practice impacts on symptom control, essentially the
dyspnoea, and this has a clear effect on the QoL of the
patient [27] whereas other more objective parameters
(such as spirometry data) are not always related so directly
with this aspect. An objective measure of dyspnoea can be
obtained with the modified scale of the Medical Research
Council [28,29]. Questionnaires specifically related to
COPD, and adapted for our environment, are the St
George's Respiratory Questionnaire (SGRQ) [30,31] and
the Chronic Respiratory Disease Questionnaire (CRQ)
[32,33], and these are useful tools in evaluating the effec-
tiveness of the interventions in these patients.
Clinical Practice Guidelines (CPG) advocate implement-
ing health education programs during the follow-up of
the disease. Educational interventions need to include
aspects such as positive motivational reinforcement, anti-
smoking advice, information on diet and physical exer-
cise, compliance with the therapeutic regimen, and verifi-
cation of the correct inhaler technique [6,7,9,34]. One of
the most useful strategies in achieving a change in life-
style habits is the motivational interview. However, this is
conducted irregularly, and with little structure. In explor-
ing the attitude of the patients in relation to their health-
related life-style activities, the General Health Survey of
the Cancer Prevention Research Center [35] is useful since
it responds to the patient's intention towards the habit (to
continue or to discontinue). This exploration enables an
assessment to be made regarding the stage prior to the
evolution of change which, according to Prochasha and
Diclemente [36,37] can help establish a therapeutic plan.
In our Spanish environment there is little tradition of
health education programs for patients with COPD, while
those that do exist focus on aspects of training in the use
of inhalers and, in individual consultation, on the man-
agement of the smoking habit. It advised that respiratory
rehabilitation be performed within the treatment plan for
the patient with COPD [6] but this is precluded by the
lack of sufficient numbers of health-care professionals,
the time or adequate space in which to implement an
appropriate level of service at the PC level and a low
implementation of specific programs for this pathology,
including a multi-disciplinary approach to the disease.
In relation to drug-based treatment, studies performed in
Spain show that outpatient treatment of the disease in PC
is far from the evidence-based recommendations for daily
clinical practice [28].
In the real world of PC, the health-care professionals have
a multitude of guidelines to follow and decisions are often
taken that are highly variable. As such, a standardisation
of CPG would be useful if disseminated and implemented
correctly [38] using a well-regulated training plan. There
are few studies that have explored the implementation of
CPG in patients with COPD, not only nationally but inter-
nationally as well and, of these, the majority have evalu-
ated only the pharmaceutical viewpoint [32,39].
Also needing highlighting is the importance of health-care
professionals making clinical information available to
their patients with COPD. Currently, there are only a few
of these aspects that the teams of health-care professionals
in the PCC make available to the patients. These include
spirometry and vaccinations and, for the individual, the
profiles of prescription drugs. There are not many pam-
phlets and leaflets available, nor are patients provided
with individualised information and outcomes by their
health-care professionals (control of symptoms, spirome-
try results, QoL) which can improve standard clinical
practice. But there has been a change in the information
provided on prescription medications and the use of diag-
nostic tests [40].
Hence, we developed the current project which focuses on
evaluating the effectiveness of a combined strategy
directed towards health-care professionals as well as the
patients in order to improve the grade of clinical control/
monitoring and the QoL of patients with COPD. The pro-
gram involves individual patient health-status informa-
tion feedback to their health-care professionals, a plan of
training of health-care professionals based on a CPG [7]
involving aspects of health education, and the implemen-
tation of the program when the patient visits the PCC.
The specific objectives are: a) to describe the current status
of patients with COPD attending PCC. The evaluations
include the principal socio-demographic variables, risk
factors, prevalence, clinical monitoring and follow-up, the
consumption of health-care resources, drugs, health
advice and QoL; b) to evaluate the grade of compliance
with the recommendations of the CPG [7] in monitoring
COPD; and c) to evaluate the possible life-style changes
(tobacco habit, diet and physical exercise) that may be
spontaneous and/or taken-up following the implementa-
tion of the health-care intervention.
Methods/Design
This is a multi-centred, before-after, quasi experimental,
prospective study involving an intervention and a control
group of individuals followed-up for 12 months (Figure
1).
Participation in the study was offered to all the urban and
semi-urban PCC within our health-area administrative
remit (52 PCC of which 21 took-up the invitation to par-
ticipate). All the patients corresponding to the PCC of one
s u b - a r e a  ( n  =  9 )  ( S A P  B a i x  L L o b r e g a t  C e n t r e )  w e r e
assigned to the intervention group and the patients fromBMC Public Health 2009, 9:442 http://www.biomedcentral.com/1471-2458/9/442
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Algorithm of the study Figure 1
Algorithm of the study.
Patients of both genders aged 40 years of age, 
recorded as having COPD, receiving attention in 
the PCC or at home, who have had at least one 
clinical visit for COPD management, and who 
provide written informed consent to participation 
in the study.
Exclusion criteria: 
Psychiatric disturbances, severe 
visual or auditory impairment, 
asthma, tuberculosis or other 
chronic respiratory pathologies, 
or any end-stage disease, or not 
having access to a telephone. 
Assignment performed by 
basic health-care unit (BHU) 
Follow-up 12 months 
-Information feed-back to the health-care 
professionals (clinician and nurse) generated 
from the clinical history and from the patient 
interview 
Information feed-back to the health-care 
professionals generated from the clinical history 
and from the patient interview. 
Training provided to the health-care 
professionals based on a course of 20h in which 
the aspects considered are: CPG, motivational 
interview, treatment of the tobacco habit, correct 
use of inhalers, diets, physical exercise, 
physiotherapy
Implementation in the PCC of the health-
education program to patients with COPD by 
those who have received the training 
Follow-up 12 months 
-Information feed-back to the health-care 
professionals (clinician and nurse) generated 
from the clinical history and from the patient 
interview 
Standard/normal care 
CONTROL 
Individual/BHU  
[12PCC]
INTERVENTION 
Individual/BHU 
[9PCC]  
Enter study 
Informed consent 
Target population BMC Public Health 2009, 9:442 http://www.biomedcentral.com/1471-2458/9/442
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the rest of the PCCs (n = 21) in the administrative area
(L'Hospitalet, Baix Llobregat Nord, Litoral i Alt Penédes-
Garraf) were assigned to the control group
Given that this project is based on an overall strategy for
the management of COPD involving a training program
for health-care professionals of the PCC and, subse-
quently, the implementation of the program by the
health-care professionals with their patients, there was no
randomisation performed. This assignment was per-
formed for logistic reasons and to maximise the benefit
while minimising the contamination effect between
PCCs. Since the PCCs are from the same metropolitan
area of Barcelona, there are not expected to be any signif-
icant differences in terms of socio-economic and educa-
tion levels that could affect outcomes.
Study subjects
The subjects include all patients diagnosed as having
COPD attending the PCC for the management of their
pathology over the previous year. Inclusion criteria are:
patients of both genders aged ≥ 40 years of age, recorded
as having COPD, receiving attention in the PCC or at
home, who have had at least one clinical visit for COPD
management, and who provide written informed consent
to participation in the study.
Exclusion criteria are: patients who have any psychiatric
disturbances, severe visual or auditory impairment that
would impede compliance with the study protocol,
patients with asthma, tuberculosis or other chronic respi-
ratory pathologies, or any end-stage disease, or not having
access to a telephone.
Sample selection process
The proposal to participate in the project was put to all the
health-care professionals (clinicians and nurses) organ-
ised as basic health-care units (BHU); 87 BHUs corre-
sponding to 21 PCCs participated in the study.
Recruitment of patients
Since 2003, some centres had computerised their records
while others have been in the process of computerisation
but, currently, retain hardcopy (paper) clinical histories.
Hence the recruitment is performed in different ways
depending on the type of records being kept. In 8 centres
that are not computerised, a list of patients ≥ 40 years of
age was solicited from each participating BHU and, from
which, the team investigator identifies the COPD patients
from the clinical history. In 13 computerise centres, the
team investigator solicits a list of the patients ≥ 40 years of
age with the COPD diagnosis (Codes ICD-10: J43 or J44
or Codes ICPC-2: R79 or R95) in the database of the com-
puterised clinical history (e-CAP or OMI-AP) from each
participating BHU.
The BHU health-care professionals contact consecutive
COPD patients via the telephone and, following the
sequence on the list, solicit verbal consent to participa-
tion. Following the agreement to participation, an
appointment is made for a clinical consultation at the
PCC, or at the patient's home.
Sample size calculations
The variable used for the calculation of sample size is the
improvement in QoL according to the St. George's Respi-
ratory Questionnaire (SGRO) with a score of 0 to 100. To
detect a difference of ≥ 4.3 units between QoL scores of
the two groups, the minimum number required would be
393 subjects in the control group and 393 patients in the
intervention group. Assumptions are: a standard devia-
tion value in the control group of 20.4 and the estimated
rate of loss to follow-up of 10% [41,42]. The calculation
has an α risk set at 0.05 and a β risk set at 0.20 in a two-
tailed test.
Intervention
The intervention consists of:
- Information feed-back to the health-care profession-
als (clinician and nurse) generated from the clinical
history and from the patient interview
- Training provided to the health-care professionals
based on a course of 20 h in which the aspects consid-
ered are: CPG, motivational interview, treatment of
the tobacco habit, correct use of inhalers, diets, physi-
cal exercise, physiotherapy
- Implementation in the PCC of the health-education
program to patients with COPD by those who have
received the training
To be able to evaluate the efficacy of this intervention, the
comparison is between the intervention group and the
control group (formed of patients attended-to by the
health-care professionals who did not attend the training
course). The pre-intervention data collection is from the
year 2004 and, after 1 year, the same information is col-
lected post-intervention.
Variables recorded
￿ QoL: variable collected using the SGRQ. This is a
questionnaire designed to be used in diseases of
obstructive airways, COPD and asthma [30], trans-
lated into Spanish [31]. It is self-administered and is
composed of 76 items grouped on 3 scales or dimen-
sions: symptoms, activity (activity that cause or are
limited by dyspnoea) and impact (social functioning
and psychological trauma caused by the respiratory
disease). The scoring for each dimension and totalBMC Public Health 2009, 9:442 http://www.biomedcentral.com/1471-2458/9/442
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score is from 0 to 100. High scores indicate a poor QoL
and a change of 4.3 or more points is considered a sig-
nificant change in the QoL of the patient.
￿ Dyspnoea: variable collected using the modified
scale of the Medical Research Council (MRC) [28]
with the following values:
0 = Absence of dyspnoea, except when performing
intense exercise
1 = Dyspnoea on rapid walking or up a slight slope
2 = Inability to maintain, on a flat surface, the pace of
other persons of the same age due to difficulty in
breathing and requiring a stop to recover and to pro-
ceed at one's own pace
3 = The need to stop to rest when walking about 100
meters, or for a few minutes while walking at one's
own pace
4 = Dyspnoea that impedes the patient going out of
the home or in activities such as dressing and undress-
ing
￿ Number of exacerbations and hospitalizations in the
previous year
￿ Evaluation of the inhaler technique used by the
patient: This is performed using a practical test involv-
ing evaluating the step-by-step inhalation technique
according to the guidelines of the Spanish Society of
Pneumology and Thoracic Surgery [Sociedad Española
de Neumología y Cirugía Torácica; SEPAR] and the
Spanish Society of Family and Community Medicine
[Sociedad Española de Medicina Familiar y Comunitaria;
SEMFYC] [43,44]. The technique is broken-down into
several manoeuvres specific for the type of inhaler
being used. One point is assigned for each manoeuvre
correctly performed. A technique is considered to have
been correctly performed if the score achieved is 9 or
more [45].
￿ Stage assessed by spirometry [46]. The Forced Respi-
ratory Volume in the first second (FEV1) is the spiro-
metric parameter that is used to define the severity and
to establish the functional classification [46] i.e.
Stage I slight: FEV1 ≥ 80%
Stage II moderate: 50% ≤ FEV1<80%
Stage III severe: 30% ≤ FEV1<50%
Stage IV very severe: FEV1 <30%
￿ Tobacco consumption:
- Never smoked
- Ex-smoker (one or more years since quitting
smoking)
- Current smoker
Other variables
￿ Socio-demographic: date of birth, gender, education
level (no formal education, primary, secondary, uni-
versity), country of origin, occupation over the last 10
years of employment according to the National Classi-
fication of Occupations [47].
￿ Risk factors: nicotine dependency according to the
classification of Fagerström (high, medium, low),
exposure (years) in the workplace (mines, textile, glass
or plastic) and the environment (passive smoker, liv-
ing close to a site of environmental contamination),
and diseases associated with COPD (bronchial hyper-
trophy and atopia, respiratory infections in infancy
and alpha-1 antitrypsin deficiency).
￿ Co-morbidity: arterial hypertension, diabetes melli-
tus II, dyslipidaemia, active cardiovascular disease,
level of cardiovascular disease risk
￿ Life-style: regular exercise (a minimum of 23-30
minutes/day and 2-3 days/week), balanced diet (fruit
and vegetables twice a day; bread, pasta, rice, other
cereals and potatoes: 4-6 portions/day; cheese,
yoghurt and milk: 2-4 potions/day; fish, chicken or
eggs: 2 times/day; red meat, pork, sweet foods: 1 por-
tion/week or less).
￿ Recorded at the time of the diagnosis: date (month
and year) of the diagnosis of COPD, criteria of chronic
bronchitis and emphysema.
￿ Tests solicited at the time of diagnosis: spirometry
(FEV1 value and spirometry stage, chest X-ray, gasom-
etry (PO2, Sat02, CO2), electrocardiogram, blood anal-
yses, weight and height and body mass index (BMI).
￿ Chronic symptomatology: presence of cough and
sputum/expectoration over the past year
￿ Complications: presence of chronic cor pulmonaleBMC Public Health 2009, 9:442 http://www.biomedcentral.com/1471-2458/9/442
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￿ Characteristics of the exacerbations during the previ-
ous year: date, symptoms (dyspnoea, increase and
purulence of sputum, fever); site of care received
(PCC, emergency in PC, emergency in hospital); hos-
pital stay; reason for not accessing PC attention (holi-
day or long waiting time at the PCC); treatment
received (oxygen, oral corticotherapy, antibiotics,
inhalers); need for secondary assistance; site of sec-
ondary assistance (PCC; PC emergency, hospital emer-
gency); days admitted to hospital via own initiative or
referral from PC.
￿ Care resources used in the previous year: PC consul-
tations (outpatient and/or home based); specialist
attention (public/private); rehabilitation services and
physiotherapy
￿ Number of visits recorded in the clinical history in
the previous year performed by: the doctor, nurse, spe-
cialist pneumologist
￿ Clinical opinion (pneumologist): doubts in the
diagnosis, poor response to treatment, COPD moder-
ate or severe, indication for home-based continuous
oxygenotherapy (HCO), indication for volume reduc-
tion surgery or transplant, diagnosis of emphysema in
patients >45 years of age, suspicion of obstructive
apnoea syndrome (OAS) during sleep.
￿ Complementary tests solicited in the previous 2
years and in the follow-up of the patients with COPD:
spirometry (FEV1 value in the clinical history or
spirometry) gasometry (PO2, SatO2, CO2), haemat-
ocrit, electrocardiogram and body mass index calcula-
tion (BMI, weight and height); date of the
measurements conducted.
￿ Preventive measures performed in the previous year.
Advice on health education: anti-smoking advice,
treatment of the tobacco habit (substitutes for nico-
tine), diet, physical exercise, complementary treat-
ment, workplace and environmental exposure;
immunisation (influenza and pneumococcus over the
previous 5 years).
￿ Pharmacological treatment: Active prescriptions
indicated for all the pathologies (listed by commercial
name and number). Active prescription with indica-
tion for COPD:
➢ Bronchodilators:
- β2 short acting adrenergic inhalators: Salbuta-
mol, Terbutaline, Fenoterol, Procaterol
- β2 long acting adrenergic inhalators: Salmeterol,
Formoterol
-Anticolinergic inhalators: Ipratropium, Tiotro-
pium
- Methylxantins: Theophylline, Etamiphylline
➢ Glucocorticoids (corticoids inhalators: Budeso-
nide, Beclometasone, Fluticasone)
➢ Oral corticoid: Prednisone
➢ Other treatments for COPD:
- Antileukotrienes (Montelukast, Zafirlukast)
- Anti-inflammatories (Cromoglicate, Nedocromil,
Ketotifen),
- Oral β2 adrenergics (Bambuterol, Clembuterol,
Fenoterol, Salbutamol, Terbutaline)
- Mucolytics as standard treatment (Acetilcisteine,
Ambroxol, Bromhexine, Carbocisteine)
- Antibiotics as COPD prophylaxis
- Home-based oxygenotherapy
￿ Complimentary therapy (difficulty in taking the
medication and causes):
▪ I forgot to take the medication, I thought it
was better not to take it
▪ I am very tired and do take the medication
▪ Because I did not pick-up the medication
from the pharmacy
▪ I quit taking the medication because of side-
effects
▪ I quit taking the medication because I felt bet-
ter
▪ Because I am afraid of taking medications
▪ Because it is very expensive
▪ I just didn't take the medication
￿ Other questionsBMC Public Health 2009, 9:442 http://www.biomedcentral.com/1471-2458/9/442
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▪ Did you sometimes forget the inhaler or med-
ications indicated for the treatment of your
COPD?
▪ Do you take them at the times indicated?
▪ When you felt better did you quit the medica-
tion?
▪ Did you feel poorly when taking the medica-
tion and you decided to stop taking it?
￿ Inhalers: Number of inhalers and type of system
used (MDI; MDI+ chamber; Autohaler, Aerolizer,
Handyhaler, Turbohaler, Accuhaler)
￿ Attendance by the patient at the health-educa-
tion classes. Follow-up variables: date, type of visit
(programmed for the individual, programmed for
the group, non-programmed)
￿ Discharge or withdrawn from the study (rea-
sons): death, change of address, lost to follow-up,
others
Variables collected in follow-up (structured in 5 sections)
￿ Tobacco (diagnosis and intervention):
- Diagnosis (not evaluated, non-smoker, ex-
smoker, smoker in the phase of pre-contempla-
tion/contemplation/preparation, action/mainte-
nance/relapse)
- Intervention (treatment in PC and follow-up, no
intervention needed and the patient is congratu-
lated, advice or information, motivational inter-
view, minimal help, intensive help visits 7 days
pre-intervention, visits 2-3 days post-intervention,
visit 10-15 days post-intervention, visit in follow-
up at 2-3 months).
￿ Inhaler use (diagnosis and intervention):
- Diagnosis (not evaluated, no prescription, pre-
scription and not used, prescription used correctly,
prescription not used correctly)
- Intervention (no intervention needed and the
patient is congratulated, advice or information,
motivational interview).
￿ Exercise (diagnosis and intervention):
- Diagnosis (not evaluated, not able to perform
exercise, not performing exercise in the phase: pre-
contemplation/preparation/action/relapse/per-
forming exercise 20-30 minutes/day 2-3 days/
week, performing exercise in the maintenance
phase)
- Intervention (no intervention needed and the
patient is congratulated, advice or information,
motivational interview, personalised exercise
plan).
￿ Diet (diagnostics and intervention):
- Diagnosis (not evaluated, healthy dieting,
healthy diet in maintenance stage, non-dieting in
phase of: pre-contemplation/contemplation/prep-
aration/active/relapse)
- Intervention (no intervention needed and the
patient is congratulated, advice or information,
motivational interview, individualised diet)
￿ Respiratory physiotherapy: stretching exercise,
seated exercise, bronchial hygiene, climbing stairs
- (diagnosis and intervention evaluated in all the
above exercises):
- Diagnosis (not evaluated, not having been
shown, cannot perform exercise, exercise correctly
performed, exercise incorrectly performed)
- Intervention (no intervention needed and the
patient is congratulated, advice or information,
motivational interview).
Observations of the health-care professional
Collection of data and follow-up
In the patients from whom verbal consent to participation
in the study has been obtained, the data are collected in a
dual manner: clinical history (recorded, computerized or
on paper) followed by an interview with the patient. This
is performed in the PCC or at the patient's home. Written
informed consent to participation in the study is then
obtained. To minimise bias, the recording of the informa-
tion (clinical history/interview) is conducted by the
health-care professionals in the research team that has
previously-received instructions in standardised data col-
lection. The variables recorded in the clinical history and
in the interview are recorded again at the end of the inter-
vention period, one year later (Table 1)
The information is transferred to a specifically designed
data-collection form and subsequently introduced into a
database (Access version XP 2003) by a member of the
administrative staff for subsequent validation and analy-
ses.BMC Public Health 2009, 9:442 http://www.biomedcentral.com/1471-2458/9/442
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The reference health-care professional (clinician or nurse)
of the intervention group, following the feedback from
their COPD patients and having attended the training
program, interactively provide the health-education infor-
mation to the patients. These consultations are monitored
via a specific data-recording form (follow-up sheet) that is
completed each time the health-education program infor-
mation is provided by the clinician or the nurse to the
patient, whether in a scheduled or a spontaneous visit to
the PCC. Changes in stage (pre-contemplative/contem-
plative/preparative/action/relapse) of the life-style habits
(tobacco, diet, exercise, respiratory physiotherapy, inhala-
tor use) observed in the patient are recorded according to
theoretical model of Prochaska and Diclemente (no inter-
vention needed and the patient is congratulated/advice or
information/motivational interview/individualised
plan).
These data sheets are submitted to the project investiga-
tors on a monthly basis.
The numbers of visits that each patient needs for health
education are determined depending on the level of
change observed in the patients (taking into account the
initial status of the individual, the motivation for change
in conduct and the capacity to learn).
Analysis strategy
Initially, the descriptive statistics are calculated for all the
variables considered. These are the mean (standard devia-
Table 1: Distribution of variables according to the source and time of data collection.
Variables source Time of data collection
Clinical
history
Interview Pre-intervention Post-intervention
Principal variables
Quality of life; SGRQ x x x
Evaluation of dyspnoea; MRC x x x
Number of exacerbations x x x x
Number of hospital stays x x x x
Correct inhalation technique x x x
Spirometry staging x x x
Tobacco consumption x x x x
Other variables
Date of birth x x
Gender x x
Education level x x
Country of birth x x
Occupation during the previous 10 years x x x
Nicotine dependence x x x
Work-place exposure x x x
Environmental exposure x x x
Disease related to COPD x x
Co-morbidity x x x
Life-style xx x
Date of COPD diagnosis x x
Chronic bronchitis and emphysema x x
Co-morbidity at time of diagnosis x x
Chronic symptomatology x x x
Cor pulmonale x x x
Characteristics of the exacerbations x x x x
Health-care resources used x x x
Number of visits to the clinician/nurse/specialist, and reasons x x x
Tests solicited over the previous 2 years x x x
Preventative activities in the previous year x x x
Drug treatment x x x
Compliance with treatment (difficulties and causes) x x x x
Inhalers xx xBMC Public Health 2009, 9:442 http://www.biomedcentral.com/1471-2458/9/442
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tion) for the continuous variables with normal distribu-
tion, the median (interquartile ranges) in case of non-
normal distribution and frequency (percentage) for the
categorical variables. The differences between groups
(control vs. intervention) are evaluated using the χ2 test or
Fisher's exact test for the categorical variables and the Stu-
dent t-test for the continuous variables with normal distri-
bution, or the corresponding non-parametric Mann-
Whitney U test.
The differences between means, medians or differences in
proportions, at baseline and at the year-end (pre- and
post-intervention) are compared using the appropriate
McNemar test, the Student t-test for paired observations,
or the Wilcoxon signed rank test. An intent-to-treat analy-
sis is performed, followed by a second analysis with only
those patients who had completed the study i.e. 1 year of
follow-up. Results on prevalence are derived from the
intent-to-treat analysis.
To evaluate the degree of change pre- and post-interven-
tion, the differences in means between continuous varia-
ble values at baseline and post-intervention are adjusted
for the size effect. The size effect is calculated as the differ-
ence between the mean at baseline and the measure at the
end of follow-up divided by the baseline standard devia-
tion value. This approximation is considered the size
effect and is a standard measure of the change in a
"before-after" study [48]. As defined by Cohen, a size
effect of 0.20 is considered small, 0.50 as moderate, and
0.80 as large [49]. Analysis of covariance adjusted for the
baseline values are performed as well.
The percentage change relative to baseline is used as a
measure of change pre- and post-intervention in the cate-
gorical variables and is presented as the difference
between the final percentage minus the initial percentage
× 100.
Multivariate regression analyses are performed using the
intervention/control group as dependent variable with
the possible independent predictive variables and those
that are considered clinically relevant adjusted for the
baseline values. The level of significance is set at p < 0.05.
The SPSS package, version 16.0 is used throughout
Ethical aspects of the study
The protocol has been studied and approved by the CEIC
-Comité Ético de Investigación Clínica (Clinical Investigation
Ethical Committee) of the Institut d'Investigació Primària
Jordi Gol [IDIAP-Jordi Gol]. Consent is obtained from the
health-care professionals and from the patients for the
collection of clinical history data. Data confidentiality of
the patients and of the participating health-care profes-
sionals are maintained at all times. The data are used only
for the scientific purposes of the study and anonymity is
guaranteed in the presentation of the results.
Discussion
Limitations of the study
A major bias of the study is that there is no randomisation
of the health-care professionals and of the participating
centres. This is a quasi-experimental study in which the
investigators control the exposure variable, but not the
randomisation variable, and this can affect the external
validity. Another possible bias is the restrictive criteria of
patient selection. Included in the study are patients who
can cope with an interview, even at home. Conversely, not
included are those patients who, at the time of the inter-
view, are unable to respond to the questions. This can
affect the generalisability of the results.
One aspect needing to be taken into account is that the
study does not compare whether the diagnosis of COPD
has been done correctly. In recent years in PC, the diagno-
sis and management of COPD has been considered defi-
cient. Recent studies indicate that only between 38 and
45% of patients at high risk have had a diagnostic spiro-
metric analysis performed by the clinician in the PCC
[20,24-26]. The most frequent explanations for this low
percentage are: the lack of awareness of the impact of the
test, unfamiliarity, lack of training, shortage of personnel
and time, and the difficulty in interpreting the test
[26,50,51]. European studies such as that by Rutschmann
et al have shown that 82% of the clinicians in PC consider
spirometry as the most appropriate method for the diag-
nosis of COPD while only 55% of them explicitly use the
test and only 33% know the correct GOLD diagnostic cri-
teria [14].
Of note is the low availability of the spirometric equip-
ment in the PCC. Until quite recently the equipment was
available in only 50% of PCCs [50,51]. Also, there is the
lack of training of the technician in charge of performing
the test and of maintaining regular quality control checks
on the equipment. Even when these checks have been
done, early studies showed a low level of quality control
[52].
Hence, we decided to include patients whose clinical his-
tory notes included the term COPD in the diagnosis sec-
tion without confirming whether or not spirometric
testing had been performed, or that the result of the test
corresponded to the obstructive pattern. This is acceptable
within the framework of the present study because the
objective of the study is not to validate the diagnosis but
to evaluate the characteristics of the standard care pro-
vided in the PCC by the health-care professionals, and the
response to an intervention program.BMC Public Health 2009, 9:442 http://www.biomedcentral.com/1471-2458/9/442
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Another aspect warranting comment is that in this study
only a single spirometric value was derived, the FEV1. This
is because this is the most-frequently registered value in
the clinical history of these patients and indicates the
severity stage of the disease. As has been described in
other studies which refer to the interpretation of spirome-
try results, apart from FEV1 all the remaining parameters
show wide variation with a high percentage of values lying
beyond the intervals considered plausible. Hence, the
FEV1 is considered more reliable than the other parame-
ters [53,54].
The present study provides us with a global as well as a
detailed view of the treatment and follow-up of the
patients with COPD receiving attention in PC. However,
the results will need to be compared with other compara-
ble studies.
Applicability in the clinic
The study provides insight into standard clinical practice
of the health-care professionals in relation to patients
with COPD receiving attention in PC. At the same time it
enables us to evaluate the possible changes that can
appear naturally and, following an intervention, in the
management of these patients and, consequently, to eval-
uate the appropriateness of these recommendations in
CPG. As such, the study can have a special relevance since
the majority of the studies previously conducted have
focused on treatment with pharmaceutical products. The
current study, on the other hand, attempts to provide a
more global view of the correct management of patients
with COPD. The results of the study would highlight the
need for the correct application of diagnostic criteria that
are currently recommended by CPG.
The smoking habit is, currently, the best known causal fac-
tor and the cessation of the habit is the only method that
can prevent the disease and to modify its clinical evolu-
tion. Intervention in the PCC with respect to this risk fac-
tor is fundamental given that the health-care
professionals, especially nurses, are very accessible to the
public not only in the PCC but also in the community. As
such, they represent effective instruments to motivate and
to follow-up more intensively those patients who smoke.
However, according to our literature search, the percent-
age of success in anti-tobacco programs is low. We con-
sider it vital that the management of the smoking habit is
broadened by encouraging the health-care professionals
towards intervention by improving their training and
awareness of the disease. This is an aspect the current
project seeks to address.
In PC outpatient clinics, especially those managed by
nursing staff, much effort is dedicated towards a few
chronic pathologies such as diabetes, hypertension and
obesity, while lacking a focus on other groups of patients
with other chronic pathologies which could also benefit
from such efforts.
The literature shows that non-pharmacological treatment,
such as exercise and rehabilitation, can be useful in
improving the exercise tolerance of the patients with
COPD, essentially with respect to dyspnoea which is the
symptom that most affects the QoL of the patient.
This project will confirm the need to support the workers
in PC in attending to their patients with COPD in a pro-
grammed manner, to conduct health-education programs
with the objective of improving the symptomatology, to
diminish exacerbations, and to diminish the consump-
tion of prescription drugs and health-care resources.
This project provides an overview of interventions that
can improve the overall quality-of-life of the patients with
COPD. Conduct modification or resource increases are
needed when motivating the health-care professionals
who, perhaps, are not fully aware of the overall health-
care status of their patients. As such, we consider it of con-
siderable value to inform the health-care professionals of
those aspects that are susceptible to modification based
on the information received from their outpatient clinics.
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